Frequência de autoanticorpos e dosagem de complemento sérico em pacientes com diagnóstico de leishmaniose cutânea ou visceral Frequency of autoantibodies and serum complement levels in patients with visceral or cutaneous leishmaniasis
INTRODUÇÃO: A leishmaniose é uma doença infecciosa crônica que pode variar de um espectro que inclui o acometimento cutâneo isolado com manifestação oligossintomática até o acometimento sistêmico com manifestações clínicas importantes. O desenvolvimento de infecção em cada tipo de leishmaniose (visc...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Alex Magno Coelho Horimoto [verfasserIn] Izaias Pereira da Costa [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch ; Spanisch ; Portugiesisch |
| Erschienen: |
2009 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Revista Brasileira de Reumatologia - Sociedade Brasileira de Reumatologia, 2005, 49(2009), 5, Seite 529-546 |
|---|---|
| Übergeordnetes Werk: |
volume:49 ; year:2009 ; number:5 ; pages:529-546 |
| Links: |
Link aufrufen |
|---|
| DOI / URN: |
10.1590/S0482-50042009000500005 |
|---|
| Katalog-ID: |
DOAJ036535958 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ036535958 | ||
| 003 | DE-627 | ||
| 005 | 20230307231843.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2009 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1590/S0482-50042009000500005 |2 doi | |
| 035 | |a (DE-627)DOAJ036535958 | ||
| 035 | |a (DE-599)DOAJ3eb8a6e3cafc4240bb383f4d098fbcc4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a spa |a por | ||
| 050 | 0 | |a RC925-935 | |
| 100 | 0 | |a Alex Magno Coelho Horimoto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Frequência de autoanticorpos e dosagem de complemento sérico em pacientes com diagnóstico de leishmaniose cutânea ou visceral Frequency of autoantibodies and serum complement levels in patients with visceral or cutaneous leishmaniasis |
| 264 | 1 | |c 2009 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a INTRODUÇÃO: A leishmaniose é uma doença infecciosa crônica que pode variar de um espectro que inclui o acometimento cutâneo isolado com manifestação oligossintomática até o acometimento sistêmico com manifestações clínicas importantes. O desenvolvimento de infecção em cada tipo de leishmaniose (visceral ou tegumentar) depende da interação complexa e intrigante entre os fatores de virulência do patógeno e a resposta imunológica do hospedeiro. Análises de soros de pacientes infectados por Leishmania demonstraram a existência de autoanticorpos contra componentes celulares e humorais, além de imunocomplexos circulantes e anticorpos contra a imunoglobulina G (fator reumatoide). Pacientes com leishmaniose visceral podem apresentar sintomas que mimetizam o quadro clínico encontrado em pacientes com diagnóstico de Lúpus Eritematoso Sistêmico (LES), dificultando o diagnóstico precoce e tratamento. OBJETIVOS: Identificar o perfil de autoanticorpos e a dosagem de complemento em pacientes com diagnóstico de leishmaniose visceral ou tegumentar e correlacionar o quadro clínico destes pacientes com o de pacientes com diagnóstico de LES. MÉTODOS: Pesquisou-se a ocorrência de autoanticorpos e dosagem de complemento no soro de 90 pacientes, sendo 45 deles com leishmaniose visceral e 45 com a forma tegumentar. RESULTADOS: Os autoanticorpos estatisticamente significativos presentes nos pacientes com leishmaniose visceral foram: Fator Antinuclear (FAN) positivo (4,4%) ou em baixa titulação (8,9%) e anticorpo anticardiolipina do tipo IgG positivo (17,8%) ou indeterminado (8,9%). Encontrou-se, ainda, diminuição do complemento sérico C3 em 17,8% dos pacientes e anticorpo anti-Leishmania positivo < 1/80 em todos os pacientes com leishmaniose visceral. CONCLUSÕES: A forma visceral da leishmaniose pode correlacionar-se positivamente com a presença de autoanticorpos, possivelmente pelo desencadeamento de uma resposta sistêmica predominantemente humoral do tipo Th2, constituindo-se em diagnóstico diferencial obrigatório com LES, principalmente nas áreas endêmicas.<br<INTRODUCTION: Leishmaniasis is a chronic infectious disease whose spectrum can vary from isolate cutaneous involvement with oligosymptomatic manifestations to systemic involvement with clinically important manifestations. The development of the infection of each type of leishmaniasis (visceral or cutaneous) depends on a complex and intriguing interaction between virulence factors of the pathogen and the immune response of the host. Analysis of sera of with Leishmania infection demonstrates the presence of autoantibodies against cellular and humoral components, besides circulating immune complexes and anti-IgG antibodies (rheumatoid factor). Patients with visceral leishmaniasis can present symptoms that mimic Systemic Lupus Erythematosus (SLE), hindering early diagnosis and treatment. OBJECTIVES: To identify the profile of autoantibodies and complement levels of patients with visceral or cutaneous leishmaniasis and to correlate their clinical presentation to those of patients with SLE. METHODS: The presence of autoantibodies and complement levels of 90 patients, 45 with visceral leishmaniasis and 45 with cutaneous leishmaniasis, was determined. Results: The presence of statistically significant autoantibodies in patients with visceral leishmaniasis included: antinuclear antibody (ANA), positive (4.4%) or in low titers (8.9%), and IgG anticardiolipin antibody, positive (17.8%) or undetermined (8.9%). A reduction in C3 levels was also seen in 17.8% of the patients and anti-Leishmania antibodies < 1/80 in all patients with visceral leishmaniasis. CONCLUSIONS: Visceral leishmaniasis can have a positive correlation with the presence of autoantibodies, possibly by triggering a predominantly humoral, systemic, type Th2 response, representing an obligatory differential diagnosis with SLE, especially in endemic areas. | ||
| 650 | 4 | |a autoanticorpos | |
| 650 | 4 | |a dosagem de complemento | |
| 650 | 4 | |a leishmaniose visceral | |
| 650 | 4 | |a leishmaniose tegumentar | |
| 650 | 4 | |a lúpus eritematoso sistêmico | |
| 650 | 4 | |a autoantibodies | |
| 650 | 4 | |a complement levels | |
| 650 | 4 | |a visceral leishmaniasis | |
| 650 | 4 | |a cutaneous leishmaniasis | |
| 650 | 4 | |a systemic lupus erythematosus | |
| 653 | 0 | |a Diseases of the musculoskeletal system | |
| 700 | 0 | |a Izaias Pereira da Costa |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Revista Brasileira de Reumatologia |d Sociedade Brasileira de Reumatologia, 2005 |g 49(2009), 5, Seite 529-546 |w (DE-627)508330734 |w (DE-600)2223192-4 |x 18094570 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2009 |g number:5 |g pages:529-546 |
| 856 | 4 | 0 | |u https://doi.org/10.1590/S0482-50042009000500005 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/3eb8a6e3cafc4240bb383f4d098fbcc4 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042009000500005 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/0482-5004 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1809-4570 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4367 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2009 |e 5 |h 529-546 | ||
| author_variant |
a m c h amch i p d c ipdc |
|---|---|
| matchkey_str |
article:18094570:2009----::rqnidatatcroeoaedcmlmnorcepcetsodantcdlihaiscteovseafeunyfuonioisnsrmopeete |
| hierarchy_sort_str |
2009 |
| callnumber-subject-code |
RC |
| publishDate |
2009 |
| allfields |
10.1590/S0482-50042009000500005 doi (DE-627)DOAJ036535958 (DE-599)DOAJ3eb8a6e3cafc4240bb383f4d098fbcc4 DE-627 ger DE-627 rakwb eng spa por RC925-935 Alex Magno Coelho Horimoto verfasserin aut Frequência de autoanticorpos e dosagem de complemento sérico em pacientes com diagnóstico de leishmaniose cutânea ou visceral Frequency of autoantibodies and serum complement levels in patients with visceral or cutaneous leishmaniasis 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier INTRODUÇÃO: A leishmaniose é uma doença infecciosa crônica que pode variar de um espectro que inclui o acometimento cutâneo isolado com manifestação oligossintomática até o acometimento sistêmico com manifestações clínicas importantes. O desenvolvimento de infecção em cada tipo de leishmaniose (visceral ou tegumentar) depende da interação complexa e intrigante entre os fatores de virulência do patógeno e a resposta imunológica do hospedeiro. Análises de soros de pacientes infectados por Leishmania demonstraram a existência de autoanticorpos contra componentes celulares e humorais, além de imunocomplexos circulantes e anticorpos contra a imunoglobulina G (fator reumatoide). Pacientes com leishmaniose visceral podem apresentar sintomas que mimetizam o quadro clínico encontrado em pacientes com diagnóstico de Lúpus Eritematoso Sistêmico (LES), dificultando o diagnóstico precoce e tratamento. OBJETIVOS: Identificar o perfil de autoanticorpos e a dosagem de complemento em pacientes com diagnóstico de leishmaniose visceral ou tegumentar e correlacionar o quadro clínico destes pacientes com o de pacientes com diagnóstico de LES. MÉTODOS: Pesquisou-se a ocorrência de autoanticorpos e dosagem de complemento no soro de 90 pacientes, sendo 45 deles com leishmaniose visceral e 45 com a forma tegumentar. RESULTADOS: Os autoanticorpos estatisticamente significativos presentes nos pacientes com leishmaniose visceral foram: Fator Antinuclear (FAN) positivo (4,4%) ou em baixa titulação (8,9%) e anticorpo anticardiolipina do tipo IgG positivo (17,8%) ou indeterminado (8,9%). Encontrou-se, ainda, diminuição do complemento sérico C3 em 17,8% dos pacientes e anticorpo anti-Leishmania positivo < 1/80 em todos os pacientes com leishmaniose visceral. CONCLUSÕES: A forma visceral da leishmaniose pode correlacionar-se positivamente com a presença de autoanticorpos, possivelmente pelo desencadeamento de uma resposta sistêmica predominantemente humoral do tipo Th2, constituindo-se em diagnóstico diferencial obrigatório com LES, principalmente nas áreas endêmicas.<br<INTRODUCTION: Leishmaniasis is a chronic infectious disease whose spectrum can vary from isolate cutaneous involvement with oligosymptomatic manifestations to systemic involvement with clinically important manifestations. The development of the infection of each type of leishmaniasis (visceral or cutaneous) depends on a complex and intriguing interaction between virulence factors of the pathogen and the immune response of the host. Analysis of sera of with Leishmania infection demonstrates the presence of autoantibodies against cellular and humoral components, besides circulating immune complexes and anti-IgG antibodies (rheumatoid factor). Patients with visceral leishmaniasis can present symptoms that mimic Systemic Lupus Erythematosus (SLE), hindering early diagnosis and treatment. OBJECTIVES: To identify the profile of autoantibodies and complement levels of patients with visceral or cutaneous leishmaniasis and to correlate their clinical presentation to those of patients with SLE. METHODS: The presence of autoantibodies and complement levels of 90 patients, 45 with visceral leishmaniasis and 45 with cutaneous leishmaniasis, was determined. Results: The presence of statistically significant autoantibodies in patients with visceral leishmaniasis included: antinuclear antibody (ANA), positive (4.4%) or in low titers (8.9%), and IgG anticardiolipin antibody, positive (17.8%) or undetermined (8.9%). A reduction in C3 levels was also seen in 17.8% of the patients and anti-Leishmania antibodies < 1/80 in all patients with visceral leishmaniasis. CONCLUSIONS: Visceral leishmaniasis can have a positive correlation with the presence of autoantibodies, possibly by triggering a predominantly humoral, systemic, type Th2 response, representing an obligatory differential diagnosis with SLE, especially in endemic areas. autoanticorpos dosagem de complemento leishmaniose visceral leishmaniose tegumentar lúpus eritematoso sistêmico autoantibodies complement levels visceral leishmaniasis cutaneous leishmaniasis systemic lupus erythematosus Diseases of the musculoskeletal system Izaias Pereira da Costa verfasserin aut In Revista Brasileira de Reumatologia Sociedade Brasileira de Reumatologia, 2005 49(2009), 5, Seite 529-546 (DE-627)508330734 (DE-600)2223192-4 18094570 nnns volume:49 year:2009 number:5 pages:529-546 https://doi.org/10.1590/S0482-50042009000500005 kostenfrei https://doaj.org/article/3eb8a6e3cafc4240bb383f4d098fbcc4 kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042009000500005 kostenfrei https://doaj.org/toc/0482-5004 Journal toc kostenfrei https://doaj.org/toc/1809-4570 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 49 2009 5 529-546 |
| spelling |
10.1590/S0482-50042009000500005 doi (DE-627)DOAJ036535958 (DE-599)DOAJ3eb8a6e3cafc4240bb383f4d098fbcc4 DE-627 ger DE-627 rakwb eng spa por RC925-935 Alex Magno Coelho Horimoto verfasserin aut Frequência de autoanticorpos e dosagem de complemento sérico em pacientes com diagnóstico de leishmaniose cutânea ou visceral Frequency of autoantibodies and serum complement levels in patients with visceral or cutaneous leishmaniasis 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier INTRODUÇÃO: A leishmaniose é uma doença infecciosa crônica que pode variar de um espectro que inclui o acometimento cutâneo isolado com manifestação oligossintomática até o acometimento sistêmico com manifestações clínicas importantes. O desenvolvimento de infecção em cada tipo de leishmaniose (visceral ou tegumentar) depende da interação complexa e intrigante entre os fatores de virulência do patógeno e a resposta imunológica do hospedeiro. Análises de soros de pacientes infectados por Leishmania demonstraram a existência de autoanticorpos contra componentes celulares e humorais, além de imunocomplexos circulantes e anticorpos contra a imunoglobulina G (fator reumatoide). Pacientes com leishmaniose visceral podem apresentar sintomas que mimetizam o quadro clínico encontrado em pacientes com diagnóstico de Lúpus Eritematoso Sistêmico (LES), dificultando o diagnóstico precoce e tratamento. OBJETIVOS: Identificar o perfil de autoanticorpos e a dosagem de complemento em pacientes com diagnóstico de leishmaniose visceral ou tegumentar e correlacionar o quadro clínico destes pacientes com o de pacientes com diagnóstico de LES. MÉTODOS: Pesquisou-se a ocorrência de autoanticorpos e dosagem de complemento no soro de 90 pacientes, sendo 45 deles com leishmaniose visceral e 45 com a forma tegumentar. RESULTADOS: Os autoanticorpos estatisticamente significativos presentes nos pacientes com leishmaniose visceral foram: Fator Antinuclear (FAN) positivo (4,4%) ou em baixa titulação (8,9%) e anticorpo anticardiolipina do tipo IgG positivo (17,8%) ou indeterminado (8,9%). Encontrou-se, ainda, diminuição do complemento sérico C3 em 17,8% dos pacientes e anticorpo anti-Leishmania positivo < 1/80 em todos os pacientes com leishmaniose visceral. CONCLUSÕES: A forma visceral da leishmaniose pode correlacionar-se positivamente com a presença de autoanticorpos, possivelmente pelo desencadeamento de uma resposta sistêmica predominantemente humoral do tipo Th2, constituindo-se em diagnóstico diferencial obrigatório com LES, principalmente nas áreas endêmicas.<br<INTRODUCTION: Leishmaniasis is a chronic infectious disease whose spectrum can vary from isolate cutaneous involvement with oligosymptomatic manifestations to systemic involvement with clinically important manifestations. The development of the infection of each type of leishmaniasis (visceral or cutaneous) depends on a complex and intriguing interaction between virulence factors of the pathogen and the immune response of the host. Analysis of sera of with Leishmania infection demonstrates the presence of autoantibodies against cellular and humoral components, besides circulating immune complexes and anti-IgG antibodies (rheumatoid factor). Patients with visceral leishmaniasis can present symptoms that mimic Systemic Lupus Erythematosus (SLE), hindering early diagnosis and treatment. OBJECTIVES: To identify the profile of autoantibodies and complement levels of patients with visceral or cutaneous leishmaniasis and to correlate their clinical presentation to those of patients with SLE. METHODS: The presence of autoantibodies and complement levels of 90 patients, 45 with visceral leishmaniasis and 45 with cutaneous leishmaniasis, was determined. Results: The presence of statistically significant autoantibodies in patients with visceral leishmaniasis included: antinuclear antibody (ANA), positive (4.4%) or in low titers (8.9%), and IgG anticardiolipin antibody, positive (17.8%) or undetermined (8.9%). A reduction in C3 levels was also seen in 17.8% of the patients and anti-Leishmania antibodies < 1/80 in all patients with visceral leishmaniasis. CONCLUSIONS: Visceral leishmaniasis can have a positive correlation with the presence of autoantibodies, possibly by triggering a predominantly humoral, systemic, type Th2 response, representing an obligatory differential diagnosis with SLE, especially in endemic areas. autoanticorpos dosagem de complemento leishmaniose visceral leishmaniose tegumentar lúpus eritematoso sistêmico autoantibodies complement levels visceral leishmaniasis cutaneous leishmaniasis systemic lupus erythematosus Diseases of the musculoskeletal system Izaias Pereira da Costa verfasserin aut In Revista Brasileira de Reumatologia Sociedade Brasileira de Reumatologia, 2005 49(2009), 5, Seite 529-546 (DE-627)508330734 (DE-600)2223192-4 18094570 nnns volume:49 year:2009 number:5 pages:529-546 https://doi.org/10.1590/S0482-50042009000500005 kostenfrei https://doaj.org/article/3eb8a6e3cafc4240bb383f4d098fbcc4 kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042009000500005 kostenfrei https://doaj.org/toc/0482-5004 Journal toc kostenfrei https://doaj.org/toc/1809-4570 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 49 2009 5 529-546 |
| allfields_unstemmed |
10.1590/S0482-50042009000500005 doi (DE-627)DOAJ036535958 (DE-599)DOAJ3eb8a6e3cafc4240bb383f4d098fbcc4 DE-627 ger DE-627 rakwb eng spa por RC925-935 Alex Magno Coelho Horimoto verfasserin aut Frequência de autoanticorpos e dosagem de complemento sérico em pacientes com diagnóstico de leishmaniose cutânea ou visceral Frequency of autoantibodies and serum complement levels in patients with visceral or cutaneous leishmaniasis 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier INTRODUÇÃO: A leishmaniose é uma doença infecciosa crônica que pode variar de um espectro que inclui o acometimento cutâneo isolado com manifestação oligossintomática até o acometimento sistêmico com manifestações clínicas importantes. O desenvolvimento de infecção em cada tipo de leishmaniose (visceral ou tegumentar) depende da interação complexa e intrigante entre os fatores de virulência do patógeno e a resposta imunológica do hospedeiro. Análises de soros de pacientes infectados por Leishmania demonstraram a existência de autoanticorpos contra componentes celulares e humorais, além de imunocomplexos circulantes e anticorpos contra a imunoglobulina G (fator reumatoide). Pacientes com leishmaniose visceral podem apresentar sintomas que mimetizam o quadro clínico encontrado em pacientes com diagnóstico de Lúpus Eritematoso Sistêmico (LES), dificultando o diagnóstico precoce e tratamento. OBJETIVOS: Identificar o perfil de autoanticorpos e a dosagem de complemento em pacientes com diagnóstico de leishmaniose visceral ou tegumentar e correlacionar o quadro clínico destes pacientes com o de pacientes com diagnóstico de LES. MÉTODOS: Pesquisou-se a ocorrência de autoanticorpos e dosagem de complemento no soro de 90 pacientes, sendo 45 deles com leishmaniose visceral e 45 com a forma tegumentar. RESULTADOS: Os autoanticorpos estatisticamente significativos presentes nos pacientes com leishmaniose visceral foram: Fator Antinuclear (FAN) positivo (4,4%) ou em baixa titulação (8,9%) e anticorpo anticardiolipina do tipo IgG positivo (17,8%) ou indeterminado (8,9%). Encontrou-se, ainda, diminuição do complemento sérico C3 em 17,8% dos pacientes e anticorpo anti-Leishmania positivo < 1/80 em todos os pacientes com leishmaniose visceral. CONCLUSÕES: A forma visceral da leishmaniose pode correlacionar-se positivamente com a presença de autoanticorpos, possivelmente pelo desencadeamento de uma resposta sistêmica predominantemente humoral do tipo Th2, constituindo-se em diagnóstico diferencial obrigatório com LES, principalmente nas áreas endêmicas.<br<INTRODUCTION: Leishmaniasis is a chronic infectious disease whose spectrum can vary from isolate cutaneous involvement with oligosymptomatic manifestations to systemic involvement with clinically important manifestations. The development of the infection of each type of leishmaniasis (visceral or cutaneous) depends on a complex and intriguing interaction between virulence factors of the pathogen and the immune response of the host. Analysis of sera of with Leishmania infection demonstrates the presence of autoantibodies against cellular and humoral components, besides circulating immune complexes and anti-IgG antibodies (rheumatoid factor). Patients with visceral leishmaniasis can present symptoms that mimic Systemic Lupus Erythematosus (SLE), hindering early diagnosis and treatment. OBJECTIVES: To identify the profile of autoantibodies and complement levels of patients with visceral or cutaneous leishmaniasis and to correlate their clinical presentation to those of patients with SLE. METHODS: The presence of autoantibodies and complement levels of 90 patients, 45 with visceral leishmaniasis and 45 with cutaneous leishmaniasis, was determined. Results: The presence of statistically significant autoantibodies in patients with visceral leishmaniasis included: antinuclear antibody (ANA), positive (4.4%) or in low titers (8.9%), and IgG anticardiolipin antibody, positive (17.8%) or undetermined (8.9%). A reduction in C3 levels was also seen in 17.8% of the patients and anti-Leishmania antibodies < 1/80 in all patients with visceral leishmaniasis. CONCLUSIONS: Visceral leishmaniasis can have a positive correlation with the presence of autoantibodies, possibly by triggering a predominantly humoral, systemic, type Th2 response, representing an obligatory differential diagnosis with SLE, especially in endemic areas. autoanticorpos dosagem de complemento leishmaniose visceral leishmaniose tegumentar lúpus eritematoso sistêmico autoantibodies complement levels visceral leishmaniasis cutaneous leishmaniasis systemic lupus erythematosus Diseases of the musculoskeletal system Izaias Pereira da Costa verfasserin aut In Revista Brasileira de Reumatologia Sociedade Brasileira de Reumatologia, 2005 49(2009), 5, Seite 529-546 (DE-627)508330734 (DE-600)2223192-4 18094570 nnns volume:49 year:2009 number:5 pages:529-546 https://doi.org/10.1590/S0482-50042009000500005 kostenfrei https://doaj.org/article/3eb8a6e3cafc4240bb383f4d098fbcc4 kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042009000500005 kostenfrei https://doaj.org/toc/0482-5004 Journal toc kostenfrei https://doaj.org/toc/1809-4570 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 49 2009 5 529-546 |
| allfieldsGer |
10.1590/S0482-50042009000500005 doi (DE-627)DOAJ036535958 (DE-599)DOAJ3eb8a6e3cafc4240bb383f4d098fbcc4 DE-627 ger DE-627 rakwb eng spa por RC925-935 Alex Magno Coelho Horimoto verfasserin aut Frequência de autoanticorpos e dosagem de complemento sérico em pacientes com diagnóstico de leishmaniose cutânea ou visceral Frequency of autoantibodies and serum complement levels in patients with visceral or cutaneous leishmaniasis 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier INTRODUÇÃO: A leishmaniose é uma doença infecciosa crônica que pode variar de um espectro que inclui o acometimento cutâneo isolado com manifestação oligossintomática até o acometimento sistêmico com manifestações clínicas importantes. O desenvolvimento de infecção em cada tipo de leishmaniose (visceral ou tegumentar) depende da interação complexa e intrigante entre os fatores de virulência do patógeno e a resposta imunológica do hospedeiro. Análises de soros de pacientes infectados por Leishmania demonstraram a existência de autoanticorpos contra componentes celulares e humorais, além de imunocomplexos circulantes e anticorpos contra a imunoglobulina G (fator reumatoide). Pacientes com leishmaniose visceral podem apresentar sintomas que mimetizam o quadro clínico encontrado em pacientes com diagnóstico de Lúpus Eritematoso Sistêmico (LES), dificultando o diagnóstico precoce e tratamento. OBJETIVOS: Identificar o perfil de autoanticorpos e a dosagem de complemento em pacientes com diagnóstico de leishmaniose visceral ou tegumentar e correlacionar o quadro clínico destes pacientes com o de pacientes com diagnóstico de LES. MÉTODOS: Pesquisou-se a ocorrência de autoanticorpos e dosagem de complemento no soro de 90 pacientes, sendo 45 deles com leishmaniose visceral e 45 com a forma tegumentar. RESULTADOS: Os autoanticorpos estatisticamente significativos presentes nos pacientes com leishmaniose visceral foram: Fator Antinuclear (FAN) positivo (4,4%) ou em baixa titulação (8,9%) e anticorpo anticardiolipina do tipo IgG positivo (17,8%) ou indeterminado (8,9%). Encontrou-se, ainda, diminuição do complemento sérico C3 em 17,8% dos pacientes e anticorpo anti-Leishmania positivo < 1/80 em todos os pacientes com leishmaniose visceral. CONCLUSÕES: A forma visceral da leishmaniose pode correlacionar-se positivamente com a presença de autoanticorpos, possivelmente pelo desencadeamento de uma resposta sistêmica predominantemente humoral do tipo Th2, constituindo-se em diagnóstico diferencial obrigatório com LES, principalmente nas áreas endêmicas.<br<INTRODUCTION: Leishmaniasis is a chronic infectious disease whose spectrum can vary from isolate cutaneous involvement with oligosymptomatic manifestations to systemic involvement with clinically important manifestations. The development of the infection of each type of leishmaniasis (visceral or cutaneous) depends on a complex and intriguing interaction between virulence factors of the pathogen and the immune response of the host. Analysis of sera of with Leishmania infection demonstrates the presence of autoantibodies against cellular and humoral components, besides circulating immune complexes and anti-IgG antibodies (rheumatoid factor). Patients with visceral leishmaniasis can present symptoms that mimic Systemic Lupus Erythematosus (SLE), hindering early diagnosis and treatment. OBJECTIVES: To identify the profile of autoantibodies and complement levels of patients with visceral or cutaneous leishmaniasis and to correlate their clinical presentation to those of patients with SLE. METHODS: The presence of autoantibodies and complement levels of 90 patients, 45 with visceral leishmaniasis and 45 with cutaneous leishmaniasis, was determined. Results: The presence of statistically significant autoantibodies in patients with visceral leishmaniasis included: antinuclear antibody (ANA), positive (4.4%) or in low titers (8.9%), and IgG anticardiolipin antibody, positive (17.8%) or undetermined (8.9%). A reduction in C3 levels was also seen in 17.8% of the patients and anti-Leishmania antibodies < 1/80 in all patients with visceral leishmaniasis. CONCLUSIONS: Visceral leishmaniasis can have a positive correlation with the presence of autoantibodies, possibly by triggering a predominantly humoral, systemic, type Th2 response, representing an obligatory differential diagnosis with SLE, especially in endemic areas. autoanticorpos dosagem de complemento leishmaniose visceral leishmaniose tegumentar lúpus eritematoso sistêmico autoantibodies complement levels visceral leishmaniasis cutaneous leishmaniasis systemic lupus erythematosus Diseases of the musculoskeletal system Izaias Pereira da Costa verfasserin aut In Revista Brasileira de Reumatologia Sociedade Brasileira de Reumatologia, 2005 49(2009), 5, Seite 529-546 (DE-627)508330734 (DE-600)2223192-4 18094570 nnns volume:49 year:2009 number:5 pages:529-546 https://doi.org/10.1590/S0482-50042009000500005 kostenfrei https://doaj.org/article/3eb8a6e3cafc4240bb383f4d098fbcc4 kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042009000500005 kostenfrei https://doaj.org/toc/0482-5004 Journal toc kostenfrei https://doaj.org/toc/1809-4570 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 49 2009 5 529-546 |
| allfieldsSound |
10.1590/S0482-50042009000500005 doi (DE-627)DOAJ036535958 (DE-599)DOAJ3eb8a6e3cafc4240bb383f4d098fbcc4 DE-627 ger DE-627 rakwb eng spa por RC925-935 Alex Magno Coelho Horimoto verfasserin aut Frequência de autoanticorpos e dosagem de complemento sérico em pacientes com diagnóstico de leishmaniose cutânea ou visceral Frequency of autoantibodies and serum complement levels in patients with visceral or cutaneous leishmaniasis 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier INTRODUÇÃO: A leishmaniose é uma doença infecciosa crônica que pode variar de um espectro que inclui o acometimento cutâneo isolado com manifestação oligossintomática até o acometimento sistêmico com manifestações clínicas importantes. O desenvolvimento de infecção em cada tipo de leishmaniose (visceral ou tegumentar) depende da interação complexa e intrigante entre os fatores de virulência do patógeno e a resposta imunológica do hospedeiro. Análises de soros de pacientes infectados por Leishmania demonstraram a existência de autoanticorpos contra componentes celulares e humorais, além de imunocomplexos circulantes e anticorpos contra a imunoglobulina G (fator reumatoide). Pacientes com leishmaniose visceral podem apresentar sintomas que mimetizam o quadro clínico encontrado em pacientes com diagnóstico de Lúpus Eritematoso Sistêmico (LES), dificultando o diagnóstico precoce e tratamento. OBJETIVOS: Identificar o perfil de autoanticorpos e a dosagem de complemento em pacientes com diagnóstico de leishmaniose visceral ou tegumentar e correlacionar o quadro clínico destes pacientes com o de pacientes com diagnóstico de LES. MÉTODOS: Pesquisou-se a ocorrência de autoanticorpos e dosagem de complemento no soro de 90 pacientes, sendo 45 deles com leishmaniose visceral e 45 com a forma tegumentar. RESULTADOS: Os autoanticorpos estatisticamente significativos presentes nos pacientes com leishmaniose visceral foram: Fator Antinuclear (FAN) positivo (4,4%) ou em baixa titulação (8,9%) e anticorpo anticardiolipina do tipo IgG positivo (17,8%) ou indeterminado (8,9%). Encontrou-se, ainda, diminuição do complemento sérico C3 em 17,8% dos pacientes e anticorpo anti-Leishmania positivo < 1/80 em todos os pacientes com leishmaniose visceral. CONCLUSÕES: A forma visceral da leishmaniose pode correlacionar-se positivamente com a presença de autoanticorpos, possivelmente pelo desencadeamento de uma resposta sistêmica predominantemente humoral do tipo Th2, constituindo-se em diagnóstico diferencial obrigatório com LES, principalmente nas áreas endêmicas.<br<INTRODUCTION: Leishmaniasis is a chronic infectious disease whose spectrum can vary from isolate cutaneous involvement with oligosymptomatic manifestations to systemic involvement with clinically important manifestations. The development of the infection of each type of leishmaniasis (visceral or cutaneous) depends on a complex and intriguing interaction between virulence factors of the pathogen and the immune response of the host. Analysis of sera of with Leishmania infection demonstrates the presence of autoantibodies against cellular and humoral components, besides circulating immune complexes and anti-IgG antibodies (rheumatoid factor). Patients with visceral leishmaniasis can present symptoms that mimic Systemic Lupus Erythematosus (SLE), hindering early diagnosis and treatment. OBJECTIVES: To identify the profile of autoantibodies and complement levels of patients with visceral or cutaneous leishmaniasis and to correlate their clinical presentation to those of patients with SLE. METHODS: The presence of autoantibodies and complement levels of 90 patients, 45 with visceral leishmaniasis and 45 with cutaneous leishmaniasis, was determined. Results: The presence of statistically significant autoantibodies in patients with visceral leishmaniasis included: antinuclear antibody (ANA), positive (4.4%) or in low titers (8.9%), and IgG anticardiolipin antibody, positive (17.8%) or undetermined (8.9%). A reduction in C3 levels was also seen in 17.8% of the patients and anti-Leishmania antibodies < 1/80 in all patients with visceral leishmaniasis. CONCLUSIONS: Visceral leishmaniasis can have a positive correlation with the presence of autoantibodies, possibly by triggering a predominantly humoral, systemic, type Th2 response, representing an obligatory differential diagnosis with SLE, especially in endemic areas. autoanticorpos dosagem de complemento leishmaniose visceral leishmaniose tegumentar lúpus eritematoso sistêmico autoantibodies complement levels visceral leishmaniasis cutaneous leishmaniasis systemic lupus erythematosus Diseases of the musculoskeletal system Izaias Pereira da Costa verfasserin aut In Revista Brasileira de Reumatologia Sociedade Brasileira de Reumatologia, 2005 49(2009), 5, Seite 529-546 (DE-627)508330734 (DE-600)2223192-4 18094570 nnns volume:49 year:2009 number:5 pages:529-546 https://doi.org/10.1590/S0482-50042009000500005 kostenfrei https://doaj.org/article/3eb8a6e3cafc4240bb383f4d098fbcc4 kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042009000500005 kostenfrei https://doaj.org/toc/0482-5004 Journal toc kostenfrei https://doaj.org/toc/1809-4570 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 49 2009 5 529-546 |
| language |
English Spanish Portuguese |
| source |
In Revista Brasileira de Reumatologia 49(2009), 5, Seite 529-546 volume:49 year:2009 number:5 pages:529-546 |
| sourceStr |
In Revista Brasileira de Reumatologia 49(2009), 5, Seite 529-546 volume:49 year:2009 number:5 pages:529-546 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
autoanticorpos dosagem de complemento leishmaniose visceral leishmaniose tegumentar lúpus eritematoso sistêmico autoantibodies complement levels visceral leishmaniasis cutaneous leishmaniasis systemic lupus erythematosus Diseases of the musculoskeletal system |
| isfreeaccess_bool |
true |
| container_title |
Revista Brasileira de Reumatologia |
| authorswithroles_txt_mv |
Alex Magno Coelho Horimoto @@aut@@ Izaias Pereira da Costa @@aut@@ |
| publishDateDaySort_date |
2009-01-01T00:00:00Z |
| hierarchy_top_id |
508330734 |
| id |
DOAJ036535958 |
| language_de |
englisch spanisch portugiesisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ036535958</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307231843.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2009 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1590/S0482-50042009000500005</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ036535958</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ3eb8a6e3cafc4240bb383f4d098fbcc4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">spa</subfield><subfield code="a">por</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC925-935</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Alex Magno Coelho Horimoto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Frequência de autoanticorpos e dosagem de complemento sérico em pacientes com diagnóstico de leishmaniose cutânea ou visceral Frequency of autoantibodies and serum complement levels in patients with visceral or cutaneous leishmaniasis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2009</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">INTRODUÇÃO: A leishmaniose é uma doença infecciosa crônica que pode variar de um espectro que inclui o acometimento cutâneo isolado com manifestação oligossintomática até o acometimento sistêmico com manifestações clínicas importantes. O desenvolvimento de infecção em cada tipo de leishmaniose (visceral ou tegumentar) depende da interação complexa e intrigante entre os fatores de virulência do patógeno e a resposta imunológica do hospedeiro. Análises de soros de pacientes infectados por Leishmania demonstraram a existência de autoanticorpos contra componentes celulares e humorais, além de imunocomplexos circulantes e anticorpos contra a imunoglobulina G (fator reumatoide). Pacientes com leishmaniose visceral podem apresentar sintomas que mimetizam o quadro clínico encontrado em pacientes com diagnóstico de Lúpus Eritematoso Sistêmico (LES), dificultando o diagnóstico precoce e tratamento. OBJETIVOS: Identificar o perfil de autoanticorpos e a dosagem de complemento em pacientes com diagnóstico de leishmaniose visceral ou tegumentar e correlacionar o quadro clínico destes pacientes com o de pacientes com diagnóstico de LES. MÉTODOS: Pesquisou-se a ocorrência de autoanticorpos e dosagem de complemento no soro de 90 pacientes, sendo 45 deles com leishmaniose visceral e 45 com a forma tegumentar. RESULTADOS: Os autoanticorpos estatisticamente significativos presentes nos pacientes com leishmaniose visceral foram: Fator Antinuclear (FAN) positivo (4,4%) ou em baixa titulação (8,9%) e anticorpo anticardiolipina do tipo IgG positivo (17,8%) ou indeterminado (8,9%). Encontrou-se, ainda, diminuição do complemento sérico C3 em 17,8% dos pacientes e anticorpo anti-Leishmania positivo < 1/80 em todos os pacientes com leishmaniose visceral. CONCLUSÕES: A forma visceral da leishmaniose pode correlacionar-se positivamente com a presença de autoanticorpos, possivelmente pelo desencadeamento de uma resposta sistêmica predominantemente humoral do tipo Th2, constituindo-se em diagnóstico diferencial obrigatório com LES, principalmente nas áreas endêmicas.<br<INTRODUCTION: Leishmaniasis is a chronic infectious disease whose spectrum can vary from isolate cutaneous involvement with oligosymptomatic manifestations to systemic involvement with clinically important manifestations. The development of the infection of each type of leishmaniasis (visceral or cutaneous) depends on a complex and intriguing interaction between virulence factors of the pathogen and the immune response of the host. Analysis of sera of with Leishmania infection demonstrates the presence of autoantibodies against cellular and humoral components, besides circulating immune complexes and anti-IgG antibodies (rheumatoid factor). Patients with visceral leishmaniasis can present symptoms that mimic Systemic Lupus Erythematosus (SLE), hindering early diagnosis and treatment. OBJECTIVES: To identify the profile of autoantibodies and complement levels of patients with visceral or cutaneous leishmaniasis and to correlate their clinical presentation to those of patients with SLE. METHODS: The presence of autoantibodies and complement levels of 90 patients, 45 with visceral leishmaniasis and 45 with cutaneous leishmaniasis, was determined. Results: The presence of statistically significant autoantibodies in patients with visceral leishmaniasis included: antinuclear antibody (ANA), positive (4.4%) or in low titers (8.9%), and IgG anticardiolipin antibody, positive (17.8%) or undetermined (8.9%). A reduction in C3 levels was also seen in 17.8% of the patients and anti-Leishmania antibodies < 1/80 in all patients with visceral leishmaniasis. CONCLUSIONS: Visceral leishmaniasis can have a positive correlation with the presence of autoantibodies, possibly by triggering a predominantly humoral, systemic, type Th2 response, representing an obligatory differential diagnosis with SLE, especially in endemic areas.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">autoanticorpos</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">dosagem de complemento</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">leishmaniose visceral</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">leishmaniose tegumentar</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">lúpus eritematoso sistêmico</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">autoantibodies</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">complement levels</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">visceral leishmaniasis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cutaneous leishmaniasis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">systemic lupus erythematosus</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the musculoskeletal system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Izaias Pereira da Costa</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Revista Brasileira de Reumatologia</subfield><subfield code="d">Sociedade Brasileira de Reumatologia, 2005</subfield><subfield code="g">49(2009), 5, Seite 529-546</subfield><subfield code="w">(DE-627)508330734</subfield><subfield code="w">(DE-600)2223192-4</subfield><subfield code="x">18094570</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:49</subfield><subfield code="g">year:2009</subfield><subfield code="g">number:5</subfield><subfield code="g">pages:529-546</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1590/S0482-50042009000500005</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/3eb8a6e3cafc4240bb383f4d098fbcc4</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042009000500005</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0482-5004</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1809-4570</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">49</subfield><subfield code="j">2009</subfield><subfield code="e">5</subfield><subfield code="h">529-546</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
Alex Magno Coelho Horimoto |
| spellingShingle |
Alex Magno Coelho Horimoto misc RC925-935 misc autoanticorpos misc dosagem de complemento misc leishmaniose visceral misc leishmaniose tegumentar misc lúpus eritematoso sistêmico misc autoantibodies misc complement levels misc visceral leishmaniasis misc cutaneous leishmaniasis misc systemic lupus erythematosus misc Diseases of the musculoskeletal system Frequência de autoanticorpos e dosagem de complemento sérico em pacientes com diagnóstico de leishmaniose cutânea ou visceral Frequency of autoantibodies and serum complement levels in patients with visceral or cutaneous leishmaniasis |
| authorStr |
Alex Magno Coelho Horimoto |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)508330734 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RC925-935 |
| illustrated |
Not Illustrated |
| issn |
18094570 |
| topic_title |
RC925-935 Frequência de autoanticorpos e dosagem de complemento sérico em pacientes com diagnóstico de leishmaniose cutânea ou visceral Frequency of autoantibodies and serum complement levels in patients with visceral or cutaneous leishmaniasis autoanticorpos dosagem de complemento leishmaniose visceral leishmaniose tegumentar lúpus eritematoso sistêmico autoantibodies complement levels visceral leishmaniasis cutaneous leishmaniasis systemic lupus erythematosus |
| topic |
misc RC925-935 misc autoanticorpos misc dosagem de complemento misc leishmaniose visceral misc leishmaniose tegumentar misc lúpus eritematoso sistêmico misc autoantibodies misc complement levels misc visceral leishmaniasis misc cutaneous leishmaniasis misc systemic lupus erythematosus misc Diseases of the musculoskeletal system |
| topic_unstemmed |
misc RC925-935 misc autoanticorpos misc dosagem de complemento misc leishmaniose visceral misc leishmaniose tegumentar misc lúpus eritematoso sistêmico misc autoantibodies misc complement levels misc visceral leishmaniasis misc cutaneous leishmaniasis misc systemic lupus erythematosus misc Diseases of the musculoskeletal system |
| topic_browse |
misc RC925-935 misc autoanticorpos misc dosagem de complemento misc leishmaniose visceral misc leishmaniose tegumentar misc lúpus eritematoso sistêmico misc autoantibodies misc complement levels misc visceral leishmaniasis misc cutaneous leishmaniasis misc systemic lupus erythematosus misc Diseases of the musculoskeletal system |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Revista Brasileira de Reumatologia |
| hierarchy_parent_id |
508330734 |
| hierarchy_top_title |
Revista Brasileira de Reumatologia |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)508330734 (DE-600)2223192-4 |
| title |
Frequência de autoanticorpos e dosagem de complemento sérico em pacientes com diagnóstico de leishmaniose cutânea ou visceral Frequency of autoantibodies and serum complement levels in patients with visceral or cutaneous leishmaniasis |
| ctrlnum |
(DE-627)DOAJ036535958 (DE-599)DOAJ3eb8a6e3cafc4240bb383f4d098fbcc4 |
| title_full |
Frequência de autoanticorpos e dosagem de complemento sérico em pacientes com diagnóstico de leishmaniose cutânea ou visceral Frequency of autoantibodies and serum complement levels in patients with visceral or cutaneous leishmaniasis |
| author_sort |
Alex Magno Coelho Horimoto |
| journal |
Revista Brasileira de Reumatologia |
| journalStr |
Revista Brasileira de Reumatologia |
| callnumber-first-code |
R |
| lang_code |
eng spa por |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2009 |
| contenttype_str_mv |
txt |
| container_start_page |
529 |
| author_browse |
Alex Magno Coelho Horimoto Izaias Pereira da Costa |
| container_volume |
49 |
| class |
RC925-935 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Alex Magno Coelho Horimoto |
| doi_str_mv |
10.1590/S0482-50042009000500005 |
| author2-role |
verfasserin |
| title_sort |
frequência de autoanticorpos e dosagem de complemento sérico em pacientes com diagnóstico de leishmaniose cutânea ou visceral frequency of autoantibodies and serum complement levels in patients with visceral or cutaneous leishmaniasis |
| callnumber |
RC925-935 |
| title_auth |
Frequência de autoanticorpos e dosagem de complemento sérico em pacientes com diagnóstico de leishmaniose cutânea ou visceral Frequency of autoantibodies and serum complement levels in patients with visceral or cutaneous leishmaniasis |
| abstract |
INTRODUÇÃO: A leishmaniose é uma doença infecciosa crônica que pode variar de um espectro que inclui o acometimento cutâneo isolado com manifestação oligossintomática até o acometimento sistêmico com manifestações clínicas importantes. O desenvolvimento de infecção em cada tipo de leishmaniose (visceral ou tegumentar) depende da interação complexa e intrigante entre os fatores de virulência do patógeno e a resposta imunológica do hospedeiro. Análises de soros de pacientes infectados por Leishmania demonstraram a existência de autoanticorpos contra componentes celulares e humorais, além de imunocomplexos circulantes e anticorpos contra a imunoglobulina G (fator reumatoide). Pacientes com leishmaniose visceral podem apresentar sintomas que mimetizam o quadro clínico encontrado em pacientes com diagnóstico de Lúpus Eritematoso Sistêmico (LES), dificultando o diagnóstico precoce e tratamento. OBJETIVOS: Identificar o perfil de autoanticorpos e a dosagem de complemento em pacientes com diagnóstico de leishmaniose visceral ou tegumentar e correlacionar o quadro clínico destes pacientes com o de pacientes com diagnóstico de LES. MÉTODOS: Pesquisou-se a ocorrência de autoanticorpos e dosagem de complemento no soro de 90 pacientes, sendo 45 deles com leishmaniose visceral e 45 com a forma tegumentar. RESULTADOS: Os autoanticorpos estatisticamente significativos presentes nos pacientes com leishmaniose visceral foram: Fator Antinuclear (FAN) positivo (4,4%) ou em baixa titulação (8,9%) e anticorpo anticardiolipina do tipo IgG positivo (17,8%) ou indeterminado (8,9%). Encontrou-se, ainda, diminuição do complemento sérico C3 em 17,8% dos pacientes e anticorpo anti-Leishmania positivo < 1/80 em todos os pacientes com leishmaniose visceral. CONCLUSÕES: A forma visceral da leishmaniose pode correlacionar-se positivamente com a presença de autoanticorpos, possivelmente pelo desencadeamento de uma resposta sistêmica predominantemente humoral do tipo Th2, constituindo-se em diagnóstico diferencial obrigatório com LES, principalmente nas áreas endêmicas.<br<INTRODUCTION: Leishmaniasis is a chronic infectious disease whose spectrum can vary from isolate cutaneous involvement with oligosymptomatic manifestations to systemic involvement with clinically important manifestations. The development of the infection of each type of leishmaniasis (visceral or cutaneous) depends on a complex and intriguing interaction between virulence factors of the pathogen and the immune response of the host. Analysis of sera of with Leishmania infection demonstrates the presence of autoantibodies against cellular and humoral components, besides circulating immune complexes and anti-IgG antibodies (rheumatoid factor). Patients with visceral leishmaniasis can present symptoms that mimic Systemic Lupus Erythematosus (SLE), hindering early diagnosis and treatment. OBJECTIVES: To identify the profile of autoantibodies and complement levels of patients with visceral or cutaneous leishmaniasis and to correlate their clinical presentation to those of patients with SLE. METHODS: The presence of autoantibodies and complement levels of 90 patients, 45 with visceral leishmaniasis and 45 with cutaneous leishmaniasis, was determined. Results: The presence of statistically significant autoantibodies in patients with visceral leishmaniasis included: antinuclear antibody (ANA), positive (4.4%) or in low titers (8.9%), and IgG anticardiolipin antibody, positive (17.8%) or undetermined (8.9%). A reduction in C3 levels was also seen in 17.8% of the patients and anti-Leishmania antibodies < 1/80 in all patients with visceral leishmaniasis. CONCLUSIONS: Visceral leishmaniasis can have a positive correlation with the presence of autoantibodies, possibly by triggering a predominantly humoral, systemic, type Th2 response, representing an obligatory differential diagnosis with SLE, especially in endemic areas. |
| abstractGer |
INTRODUÇÃO: A leishmaniose é uma doença infecciosa crônica que pode variar de um espectro que inclui o acometimento cutâneo isolado com manifestação oligossintomática até o acometimento sistêmico com manifestações clínicas importantes. O desenvolvimento de infecção em cada tipo de leishmaniose (visceral ou tegumentar) depende da interação complexa e intrigante entre os fatores de virulência do patógeno e a resposta imunológica do hospedeiro. Análises de soros de pacientes infectados por Leishmania demonstraram a existência de autoanticorpos contra componentes celulares e humorais, além de imunocomplexos circulantes e anticorpos contra a imunoglobulina G (fator reumatoide). Pacientes com leishmaniose visceral podem apresentar sintomas que mimetizam o quadro clínico encontrado em pacientes com diagnóstico de Lúpus Eritematoso Sistêmico (LES), dificultando o diagnóstico precoce e tratamento. OBJETIVOS: Identificar o perfil de autoanticorpos e a dosagem de complemento em pacientes com diagnóstico de leishmaniose visceral ou tegumentar e correlacionar o quadro clínico destes pacientes com o de pacientes com diagnóstico de LES. MÉTODOS: Pesquisou-se a ocorrência de autoanticorpos e dosagem de complemento no soro de 90 pacientes, sendo 45 deles com leishmaniose visceral e 45 com a forma tegumentar. RESULTADOS: Os autoanticorpos estatisticamente significativos presentes nos pacientes com leishmaniose visceral foram: Fator Antinuclear (FAN) positivo (4,4%) ou em baixa titulação (8,9%) e anticorpo anticardiolipina do tipo IgG positivo (17,8%) ou indeterminado (8,9%). Encontrou-se, ainda, diminuição do complemento sérico C3 em 17,8% dos pacientes e anticorpo anti-Leishmania positivo < 1/80 em todos os pacientes com leishmaniose visceral. CONCLUSÕES: A forma visceral da leishmaniose pode correlacionar-se positivamente com a presença de autoanticorpos, possivelmente pelo desencadeamento de uma resposta sistêmica predominantemente humoral do tipo Th2, constituindo-se em diagnóstico diferencial obrigatório com LES, principalmente nas áreas endêmicas.<br<INTRODUCTION: Leishmaniasis is a chronic infectious disease whose spectrum can vary from isolate cutaneous involvement with oligosymptomatic manifestations to systemic involvement with clinically important manifestations. The development of the infection of each type of leishmaniasis (visceral or cutaneous) depends on a complex and intriguing interaction between virulence factors of the pathogen and the immune response of the host. Analysis of sera of with Leishmania infection demonstrates the presence of autoantibodies against cellular and humoral components, besides circulating immune complexes and anti-IgG antibodies (rheumatoid factor). Patients with visceral leishmaniasis can present symptoms that mimic Systemic Lupus Erythematosus (SLE), hindering early diagnosis and treatment. OBJECTIVES: To identify the profile of autoantibodies and complement levels of patients with visceral or cutaneous leishmaniasis and to correlate their clinical presentation to those of patients with SLE. METHODS: The presence of autoantibodies and complement levels of 90 patients, 45 with visceral leishmaniasis and 45 with cutaneous leishmaniasis, was determined. Results: The presence of statistically significant autoantibodies in patients with visceral leishmaniasis included: antinuclear antibody (ANA), positive (4.4%) or in low titers (8.9%), and IgG anticardiolipin antibody, positive (17.8%) or undetermined (8.9%). A reduction in C3 levels was also seen in 17.8% of the patients and anti-Leishmania antibodies < 1/80 in all patients with visceral leishmaniasis. CONCLUSIONS: Visceral leishmaniasis can have a positive correlation with the presence of autoantibodies, possibly by triggering a predominantly humoral, systemic, type Th2 response, representing an obligatory differential diagnosis with SLE, especially in endemic areas. |
| abstract_unstemmed |
INTRODUÇÃO: A leishmaniose é uma doença infecciosa crônica que pode variar de um espectro que inclui o acometimento cutâneo isolado com manifestação oligossintomática até o acometimento sistêmico com manifestações clínicas importantes. O desenvolvimento de infecção em cada tipo de leishmaniose (visceral ou tegumentar) depende da interação complexa e intrigante entre os fatores de virulência do patógeno e a resposta imunológica do hospedeiro. Análises de soros de pacientes infectados por Leishmania demonstraram a existência de autoanticorpos contra componentes celulares e humorais, além de imunocomplexos circulantes e anticorpos contra a imunoglobulina G (fator reumatoide). Pacientes com leishmaniose visceral podem apresentar sintomas que mimetizam o quadro clínico encontrado em pacientes com diagnóstico de Lúpus Eritematoso Sistêmico (LES), dificultando o diagnóstico precoce e tratamento. OBJETIVOS: Identificar o perfil de autoanticorpos e a dosagem de complemento em pacientes com diagnóstico de leishmaniose visceral ou tegumentar e correlacionar o quadro clínico destes pacientes com o de pacientes com diagnóstico de LES. MÉTODOS: Pesquisou-se a ocorrência de autoanticorpos e dosagem de complemento no soro de 90 pacientes, sendo 45 deles com leishmaniose visceral e 45 com a forma tegumentar. RESULTADOS: Os autoanticorpos estatisticamente significativos presentes nos pacientes com leishmaniose visceral foram: Fator Antinuclear (FAN) positivo (4,4%) ou em baixa titulação (8,9%) e anticorpo anticardiolipina do tipo IgG positivo (17,8%) ou indeterminado (8,9%). Encontrou-se, ainda, diminuição do complemento sérico C3 em 17,8% dos pacientes e anticorpo anti-Leishmania positivo < 1/80 em todos os pacientes com leishmaniose visceral. CONCLUSÕES: A forma visceral da leishmaniose pode correlacionar-se positivamente com a presença de autoanticorpos, possivelmente pelo desencadeamento de uma resposta sistêmica predominantemente humoral do tipo Th2, constituindo-se em diagnóstico diferencial obrigatório com LES, principalmente nas áreas endêmicas.<br<INTRODUCTION: Leishmaniasis is a chronic infectious disease whose spectrum can vary from isolate cutaneous involvement with oligosymptomatic manifestations to systemic involvement with clinically important manifestations. The development of the infection of each type of leishmaniasis (visceral or cutaneous) depends on a complex and intriguing interaction between virulence factors of the pathogen and the immune response of the host. Analysis of sera of with Leishmania infection demonstrates the presence of autoantibodies against cellular and humoral components, besides circulating immune complexes and anti-IgG antibodies (rheumatoid factor). Patients with visceral leishmaniasis can present symptoms that mimic Systemic Lupus Erythematosus (SLE), hindering early diagnosis and treatment. OBJECTIVES: To identify the profile of autoantibodies and complement levels of patients with visceral or cutaneous leishmaniasis and to correlate their clinical presentation to those of patients with SLE. METHODS: The presence of autoantibodies and complement levels of 90 patients, 45 with visceral leishmaniasis and 45 with cutaneous leishmaniasis, was determined. Results: The presence of statistically significant autoantibodies in patients with visceral leishmaniasis included: antinuclear antibody (ANA), positive (4.4%) or in low titers (8.9%), and IgG anticardiolipin antibody, positive (17.8%) or undetermined (8.9%). A reduction in C3 levels was also seen in 17.8% of the patients and anti-Leishmania antibodies < 1/80 in all patients with visceral leishmaniasis. CONCLUSIONS: Visceral leishmaniasis can have a positive correlation with the presence of autoantibodies, possibly by triggering a predominantly humoral, systemic, type Th2 response, representing an obligatory differential diagnosis with SLE, especially in endemic areas. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
| container_issue |
5 |
| title_short |
Frequência de autoanticorpos e dosagem de complemento sérico em pacientes com diagnóstico de leishmaniose cutânea ou visceral Frequency of autoantibodies and serum complement levels in patients with visceral or cutaneous leishmaniasis |
| url |
https://doi.org/10.1590/S0482-50042009000500005 https://doaj.org/article/3eb8a6e3cafc4240bb383f4d098fbcc4 http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042009000500005 https://doaj.org/toc/0482-5004 https://doaj.org/toc/1809-4570 |
| remote_bool |
true |
| author2 |
Izaias Pereira da Costa |
| author2Str |
Izaias Pereira da Costa |
| ppnlink |
508330734 |
| callnumber-subject |
RC - Internal Medicine |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1590/S0482-50042009000500005 |
| callnumber-a |
RC925-935 |
| up_date |
2024-07-03T21:08:14.603Z |
| _version_ |
1803593601104478208 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ036535958</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307231843.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2009 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1590/S0482-50042009000500005</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ036535958</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ3eb8a6e3cafc4240bb383f4d098fbcc4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">spa</subfield><subfield code="a">por</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC925-935</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Alex Magno Coelho Horimoto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Frequência de autoanticorpos e dosagem de complemento sérico em pacientes com diagnóstico de leishmaniose cutânea ou visceral Frequency of autoantibodies and serum complement levels in patients with visceral or cutaneous leishmaniasis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2009</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">INTRODUÇÃO: A leishmaniose é uma doença infecciosa crônica que pode variar de um espectro que inclui o acometimento cutâneo isolado com manifestação oligossintomática até o acometimento sistêmico com manifestações clínicas importantes. O desenvolvimento de infecção em cada tipo de leishmaniose (visceral ou tegumentar) depende da interação complexa e intrigante entre os fatores de virulência do patógeno e a resposta imunológica do hospedeiro. Análises de soros de pacientes infectados por Leishmania demonstraram a existência de autoanticorpos contra componentes celulares e humorais, além de imunocomplexos circulantes e anticorpos contra a imunoglobulina G (fator reumatoide). Pacientes com leishmaniose visceral podem apresentar sintomas que mimetizam o quadro clínico encontrado em pacientes com diagnóstico de Lúpus Eritematoso Sistêmico (LES), dificultando o diagnóstico precoce e tratamento. OBJETIVOS: Identificar o perfil de autoanticorpos e a dosagem de complemento em pacientes com diagnóstico de leishmaniose visceral ou tegumentar e correlacionar o quadro clínico destes pacientes com o de pacientes com diagnóstico de LES. MÉTODOS: Pesquisou-se a ocorrência de autoanticorpos e dosagem de complemento no soro de 90 pacientes, sendo 45 deles com leishmaniose visceral e 45 com a forma tegumentar. RESULTADOS: Os autoanticorpos estatisticamente significativos presentes nos pacientes com leishmaniose visceral foram: Fator Antinuclear (FAN) positivo (4,4%) ou em baixa titulação (8,9%) e anticorpo anticardiolipina do tipo IgG positivo (17,8%) ou indeterminado (8,9%). Encontrou-se, ainda, diminuição do complemento sérico C3 em 17,8% dos pacientes e anticorpo anti-Leishmania positivo < 1/80 em todos os pacientes com leishmaniose visceral. CONCLUSÕES: A forma visceral da leishmaniose pode correlacionar-se positivamente com a presença de autoanticorpos, possivelmente pelo desencadeamento de uma resposta sistêmica predominantemente humoral do tipo Th2, constituindo-se em diagnóstico diferencial obrigatório com LES, principalmente nas áreas endêmicas.<br<INTRODUCTION: Leishmaniasis is a chronic infectious disease whose spectrum can vary from isolate cutaneous involvement with oligosymptomatic manifestations to systemic involvement with clinically important manifestations. The development of the infection of each type of leishmaniasis (visceral or cutaneous) depends on a complex and intriguing interaction between virulence factors of the pathogen and the immune response of the host. Analysis of sera of with Leishmania infection demonstrates the presence of autoantibodies against cellular and humoral components, besides circulating immune complexes and anti-IgG antibodies (rheumatoid factor). Patients with visceral leishmaniasis can present symptoms that mimic Systemic Lupus Erythematosus (SLE), hindering early diagnosis and treatment. OBJECTIVES: To identify the profile of autoantibodies and complement levels of patients with visceral or cutaneous leishmaniasis and to correlate their clinical presentation to those of patients with SLE. METHODS: The presence of autoantibodies and complement levels of 90 patients, 45 with visceral leishmaniasis and 45 with cutaneous leishmaniasis, was determined. Results: The presence of statistically significant autoantibodies in patients with visceral leishmaniasis included: antinuclear antibody (ANA), positive (4.4%) or in low titers (8.9%), and IgG anticardiolipin antibody, positive (17.8%) or undetermined (8.9%). A reduction in C3 levels was also seen in 17.8% of the patients and anti-Leishmania antibodies < 1/80 in all patients with visceral leishmaniasis. CONCLUSIONS: Visceral leishmaniasis can have a positive correlation with the presence of autoantibodies, possibly by triggering a predominantly humoral, systemic, type Th2 response, representing an obligatory differential diagnosis with SLE, especially in endemic areas.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">autoanticorpos</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">dosagem de complemento</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">leishmaniose visceral</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">leishmaniose tegumentar</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">lúpus eritematoso sistêmico</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">autoantibodies</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">complement levels</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">visceral leishmaniasis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cutaneous leishmaniasis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">systemic lupus erythematosus</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the musculoskeletal system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Izaias Pereira da Costa</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Revista Brasileira de Reumatologia</subfield><subfield code="d">Sociedade Brasileira de Reumatologia, 2005</subfield><subfield code="g">49(2009), 5, Seite 529-546</subfield><subfield code="w">(DE-627)508330734</subfield><subfield code="w">(DE-600)2223192-4</subfield><subfield code="x">18094570</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:49</subfield><subfield code="g">year:2009</subfield><subfield code="g">number:5</subfield><subfield code="g">pages:529-546</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1590/S0482-50042009000500005</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/3eb8a6e3cafc4240bb383f4d098fbcc4</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042009000500005</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0482-5004</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1809-4570</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">49</subfield><subfield code="j">2009</subfield><subfield code="e">5</subfield><subfield code="h">529-546</subfield></datafield></record></collection>
|
| score |
7.399666 |